ProUroCare Medical Inc (CE) (PUMD) Quote

PUMD SEC Suspension because of questions regarding the adequacy and accuracy of information about the company.

https://www.sec.gov/litigation/suspensions/2020/34-88381.pdf

Order:

https://www.sec.gov/litigation/suspensions/2020/34-88381-o.pdf

Anyone got an A/S O/S here

$PUMD: She's getting alot of ATTENTION..... AWESOME

However, I only see ONE TWEET.... whats your source ?

Watchlist 2-23-18$PUMD$ECDP$RXMD$BLPG$FAGI$GIGL$PURA$RSAU$BOTY$GBBT$GLPH$AIMH$OMAG— TheWicked1ne (@TheWicked0ne) February 23, 2018

Now thats not such bad thing is it ?

Grab a ticket... take a ride.

April 19 last year it went up to $0.012


Have a GREAT DAY



GO $PUMD

She's getting PUMDed......lol

$PUMD: Is this now Artann Laboratories ?

http://www.artannlabs.com/

They have been mentioned on Artanns website as a Partner.


http://www.artannlabs.com/about-us/new-page.html


https://en.wikipedia.org/wiki/Armen_Sarvazyan

*******************************************


Business Partnerships
Artann has established business partnerships with several innovative technology companies to enhance development and commercialization of its products.

ProUroCare Medical Inc. is an emerging technology company that is developing its innovative vision in sensing technologies to increase the safety and efficacy of medical diagnostics and therapeutics. Currently, ProUroCare is primarily focused on products and technologies that are capable of identifying tissue abnormalities in the prostate using minimally invasive techniques, and on developing proprietary vision technology for thermal therapy systems to aid in the treatment of prostate related diseases. ProUroCare's first product will be the ProUroScan System, which is being designed as a unique diagnostic-visioning system that enables family physicians, internists and urologists to accurately identify and display tissue abnormalities and map the prostate.

$PUMD: Here goes $PUMD.... volume rolling in NICELY

Currently at $0.005

Has plenty of room to the upside from here


Watching it.


$PUMD

I'm not really a patent player, so just took a small position. If it works out, I'll add more.

This one is a beauty, has all the markers

Bought a few

PUMD European Patent "Grant of patent is intended"

www.tinyurl.com/kkyegzm

$PUMD: Now at $0.008..... GOoooooooooooooo

Looks good :)

HUMPDAY Happiness......... Low Floater


$PUMD

$PUMD: Well hello there.... MOVING now at $0.004

Ok... lets see what you got :)

Whats going on here at $0.004


$PUMD

See 8k filed yesterday

Anyone know why this went up 275%?

They have supposedly closed their doors, effective 31 Dec 2014.

http://www.prourocare.com/documents/Financial%20Reports/letter_to_creditors_shareholders_dec_17_2014.pdf

Who's buying and why??

Just wondering...

Higher than normal volume

LOL I'm glad I'm not alone anymore. Was a nice day today here, we'll see if it continues. :)

Boardmarked. So you're not alone anymore, lol

PUMD +50% on 243K Volume

Avg Daily Volume 1.4K

153K Buys vs 70K Sells

6 Buys of 10K or more totaling 72K or 40% of the buy volume came on 6 buys alone.

FDA Approval/Clearance will bring more eyes here!

$2.25M Financing Coming

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8546396

Under the terms of the SPA, the remaining $2.250 million funding is to be provided in six monthly tranches beginning with
a $750,000 tranche within thirty days of receiving FDA clearance followed by five $300,000 tranches

New Hires With FDA Approval

Approach to Market Entry

We have delayed the hiring of key staff positions and making certain preparations for market entry prior to FDA approval of the ProUroScan System in order to conserve cash during the prolonged FDA review period. Once we have obtained FDA approval and sufficient funding (see “Management’ Discussion and Analysis”), we plan to take the following actions over the next few months in advance of our product rollout.

· Hire the key staff needed to execute our commercialization plans. We have identified outstanding candidates in the marketing, operations, engineering, and medical reimbursement fields.


· Install ProUroScan Systems in the facilities of approximately six members of our Scientific Advisory Board to begin formal training in the use of the system, and to perform studies. We expect the work done by these respected scientists to provide the important market validation of key opinion leaders that will help facilitate market acceptance.


· Establish the internal quality control systems and capabilities required to enter the highly regulated U.S. medical device market.

Testing Done @ Mayo Clinic!

http://ih.advfn.com/p.php?pid=nmona&article=52019521

Plus many other reputable clinics!

Veterans Affairs Medical Center, Minneapolis, MN;


Robert Wood Johnson Medical School Division of Urology, New Brunswick, NJ;


Mayo Clinic, Rochester, MN;


AccuMed Research Associates, Garden City, NY; and


Urological Associates of Lancaster, Lancaster, PA.

Manufacturer Already Contracted!

http://www.logicpd.com/

http://ih.advfn.com/p.php?pid=nmona&article=52019521

Manufacturing

We have contracted with Logic PD (Minneapolis, MN), a contract engineering and manufacturing firm that is Quality Systems Regulation (“QSR”) compliant, to initiate production on the first commercial ProUroScan Systems. The QSR requires manufacturers, including certain third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process. Logic has successfully completed pre-production manufacturing of three ProUroScan Systems. The tactile pressure sensors used in the ProUroScan’s probe are supplied by Pressure Profile Systems, Inc. (“PPS”) (Los Angeles, CA), which designs and develops the world’s most advanced tactile pressure measurement systems

Because of the unique nature of the two major proprietary components of the ProUroScan System, it is likely that one or more additional third-party manufacturers will be chosen to assemble the certain components or sub-assemblies. Our goal is to reduce the cost of producing systems over the first two years, taking advantage of manufacturing scale and purchasing discounts, as well as engineering changes designed to eliminate components and reduce component costs.

ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System

http://ih.advfn.com/p.php?pid=nmona&article=52227635&symbol=PUMD

A provider of proprietary imaging products, said that it has closed on a $885,000 private placement of debt financing.

According to ProUroCare, the funding was provided by a small group of existing investors closely aligned with the company.

ProUroCare said it will use the proceeds to fund manufacturing and marketing scale-up activities, expand the company's existing intellectual property portfolio and form a scientific advisory board.

It added that a portion of the funding will also be used to pay existing debt obligations and for general corporate purposes.

Company CEO Rick Carlson said, "This additional funding brings the total amount raised by the company since 2007 to more than $9.3 million."

Minnesota-based ProUroCare Medical is engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam.